Attovia Therapeutics (ATTO) vs Monte Rosa Therapeutics (GLUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monte Rosa Therapeutics is the larger company by market cap ($840.3 million vs $710.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | GLUE |
|---|---|---|
| Share price | $15.57 | $9.85 |
| Market cap | $710.79M | $840.34M |
| 1-day change | -5.18% | -3.15% |
| YTD return | — | -35.14% |
| 1-year return | — | +37.80% |
| 5-year return | — | -52.03% |
| EPS (TTM) | $-2.74 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $25.77 |
| 52-week low | $15.48 | $7.65 |
| Distance from 52-week high | -44.39% | -61.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +171.03% | +184.26% |
| Average volume | 458.24K | 1.31M |
| Shares outstanding | 45.65M | 85.31M |
| Employees | 44 | 173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
ATTO vs GLUE FAQ
Which is bigger, Attovia Therapeutics or Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $840.34M compared with $710.79M for Attovia Therapeutics (ATTO).
Are Attovia Therapeutics and Monte Rosa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.